BIVI - BioVie EV/EBITDA Multiple

BioVie (BIVI) - corporate logo

BioVie Inc. (BIVI) focuses on developing small molecules for the treatment of neurodegeneration and severe liver pathologies. However, the business faces significant challenges, including a high burn rate and dependence on the FDA's verdict regarding the drug NE3107. The market value dynamics of the asset in terms of EV/EBITDA currently stand at 0.00. Stable management aims to successfully complete the trials, although shareholder confidence fluctuates sharply in line with research results.

BIVI (BioVie) Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization history from 11/23/2025 to 11/11/2026

Comprehensive metric breakdowns and analytics for biovieinc.com (BIVI)

- market price and analyst price targets:
Price Chart BioVie|BIVI - Price Target Chart
- market capitalization statistics:
Market Capitalization BIVI|BIVI - Company Buyout Price
- issuer book value statistics:
Accounting Value per Share BioVie|BIVI - Company Book Value|Market Capitalization to Book Value Ratio biovieinc.com|BIVI - Company Assets
- company liabilities and liquidity data:
Debt to Equity BioVie Inc.|BIVI - Long-Term Debt to Capital Coefficient|Short-Term Debt to Capital BioVie|BIVI - Company Debts|Debts to Book Capitalization BIVI|BIVI - Long-Term Debt Volume|Company Short-Term Debt BioVie|Quick Liquidity Indicator biovieinc.com
- net income and valuation multiples indicators:
BIVI - Company Net Income|Projected Future Earnings BioVie Inc.|BIVI - Business Payback Period|Forward P/E Multiple BioVie|BIVI - Price to Earnings Adjusted for Growth Rate|Enterprise Value to EBITDA Ratio BIVI|BIVI - Income before deduction of interest, taxes and amortization|Net earnings per share (EPS TTM) BioVie|BIVI - Net earnings per share for the last four quarters|Year-over-year earnings per share growth for the last twelve months biovieinc.com|BIVI - Earnings per share growth this year|Earnings growth forecast for next year BioVie Inc.
Summary company analytics:BioVie Pharma BIVI
Original product of biovieinc.com

Stable laboratory utilization and the continuity of chemical analysis at BioVie Inc. (BIVI) establish a foundation for assessing operational expenditure efficiency. An analysis of business valuation via EV/EBITDA allows for the correlation of the company's total enterprise value with its earnings before interest, taxes, depreciation, and amortization, determining whether quotes are overheated or the model has reached maturity, which is critical for understanding the issuer's capital stability.

Analysis of competing companies

Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Arrowhead Pharmaceuticals Inc ARWR|Mirum Pharmaceuticals Inc - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Dynavax Technologies Corporation - EV/EBITDA Multiple|Total Company Value to Operating Income Before Depreciation Ratio arbutusbio.com ABUS|IVA (Inventiva) - Enterprise Value to EBITDA Ratio|GYRE (Gyre Therapeutics Inc) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|ASMB (Assembly Biosciences Inc) - EV/EBITDA Multiple|Company Value to EBITDA Galectin GALT|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Genfit S.A. (GNFT)|DRRX (durect.com) - Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple ALGS (Aligos Therapeutics, Inc.)|Galmed Pharmaceuticals Ltd - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|ENDRA - EV/EBITDA Multiple|Total Company Value to Operating Income Before Depreciation Ratio Hepion Pharmaceuticals HEPA